Abacus Global Management (NYSE:ABX) announced a series of senior leadership appointments, naming a new chief accounting officer and chief investment officer as the alternative asset manager continues to expand its organizational structure.
The company said Alexei Solomon has been appointed chief accounting officer and treasurer, while Elena Plesco has been named chief investment officer.
Shares of Crocs, Inc. (NASDAQ:CROX) face a balanced risk-reward setup ahead of earnings on April 30, according to UBS, which sees a range of potential outcomes tied to first-quarter performance and guidance.
UBS’s base case calls for a modest $0.10 increase to fiscal 2026 earnings guidance, bringing it to $12.98 to $13.45 per share.
VivoPower PLC (NASDAQ:VIVO, FRA:51J) said on Tuesday it has become EBITDA profitable following the completion of its $41 million acquisition of data center assets in Norway, marking a shift to positive earnings on a pro forma basis.
The Nasdaq-listed company reported that the acquired operations are expected to contribute about $31 million in annual revenue and roughly $10 million in annual EBITDA, compared with pre-acquisition annual revenue of about $0.1 million and negative EBITDA of $8.2 million.
Argentina Lithium & Energy Corp (TSX-V:LIT, OTCQX:LILIF) has announced a non-binding agreement with China-based Xi’an Lanshen New Material Technology to advance development of its Rincon West lithium brine project in Argentina’s Salta Province.
The agreement, described as a Heads of Terms and Framework Agreement, outlines a staged approach to technical development, financing, and potential commercial production at the project.
NanoViricides (NYSE-A:NNVC) said on Tuesday its antiviral drug candidate NV-387 could help address rising measles cases globally, citing recent outbreaks and unmet treatment needs.
The company pointed to data from Bangladesh showing 18,219 suspected measles cases over the last month, with transmission reported in most districts.
Uranium American Resources Inc. (OTC:UARI) said it has completed the acquisition of JAG Minerals Pty Ltd, securing full ownership of its US subsidiary and paving the way to accelerate development of uranium and vanadium assets in Colorado and Utah.
The company said the deal, which gives it 100% control of JAG Minerals USA Inc, was amended to allow the cash portion to be settled through a four-month note payable to JAG shareholders.
1911 Gold Corp (TSX-V:AUMB, OTCQB:AUMBF, FRA:2KY) has announced the appointment of Max Satel as its new chief financial officer, as the company advances its True North gold project toward a planned production start in 2027.
Satel will oversee the company’s accounting, financial planning and analysis, tax, treasury, and strategic finance functions. He succeeds Carmen Amezquita, who will step down from the CFO role but remain with the company during a transition period.
Silver Range Resources Ltd (TSX-V:SNG, OTC:SLRRF, FRA:8SR) has significantly expanded its footprint at the Drum project in central Utah and is advancing preparations for further exploration, the company said Tuesday.
The company reported that in March it increased its land position from 7 to 37 Federal Lode Claims through additional staking. The newly acquired claims include the Rattler Breccia area and other mineral showings located to the south of the project’s previously defined core zones.
G Mining Ventures Corp (TSX:GMIN, OTCQX:GMINF, FRA:W97) said its Tocantinzinho gold mine in Brazil delivered steady first-quarter production, with output in line with expectations as the company positions for higher grades and stronger production later this year.
The company’s preliminary results showed that it produced 31,846 ounces of gold in the three months ended March 31 at its Tocantinzinho mine in Pará State, while gold sales totalled 33,776 ounces.
Shares in CRISM Therapeutics rose 19% to 14p on Tuesday after the AIM-quoted drug delivery company reported positive preclinical results for its Docetaxel-ChemoSeed implant technology in a prostate cancer model, showing a 58% reduction in tumour volume compared to standard treatment.
The study evaluated CRISM's ChemoSeed platform, which delivers chemotherapy drugs directly to tumour sites in a sustained, localised manner rather than through systemic administration, the conventional approach in which drugs are distributed throughout the body via the bloodstream.
Cavendish has retained its buy rating and 26p price target on IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) following a first-half trading update that the broker described as demonstrating strong continued revenue growth, with the neuroscience imaging and analytics company trading in line with full-year expectations.
The company reported first-half revenues expected to reach £3.9 million, up 23% year on year, driven by new contract wins, extensions and increased biomarker analysis activity, the measurement of biological indicators used to track neurological disease progression in clinical trials.
Valereum PLC (AQSE:VLRM, FRA:6TJ, OTCQB:VLRMF) said it has struck a confidential settlement with Blubird Global Inc, ending a dispute tied to its prior investment and replacing that exposure with a mix of equity and token consideration.
Under the agreement, Valereum will receive 504,824 common shares in Blubird, representing roughly 5.66% of Blubird’s fully diluted share capital. It will also receive 1.98 milllion BLU tokens, which are due to be released on a linear basis over the next 24 months.
Bango PLC (AIM:BGO, OTCQX:BGOPF) has won two direct carrier billing mandates in Hong Kong and Latvia, taking business from incumbent providers and extending its reach with mobile operators that already offer the payment method to app store users.
The AIM-listed group said Telin, a Hong Kong unit of PT Telekomunikasi Indonesia, and Latvia’s LMT both selected Bango after competitive tender processes.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and data analytics company, has reported strong first-half trading with revenues expected to rise 23% to £3.9 million for the six months ended 31 March.
The company said growth was driven by new contract wins, contract extensions and increased volumes of biomarker analysis, the measurement of biological indicators used to track disease progression in clinical trials.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) says a routine regulatory inspection of one of its Indonesian Phase 3 clinical trial sites has cleared the way for the study to continue, marking an important step forward in its push toward registration for diabetic foot infections.
The inspection, carried out by Indonesia’s National Agency of Drug and Food Control (Badan POM), reviewed trial conduct, site processes, data integrity and compliance with Good Clinical Practice standards at a site involved in the company’s Phase 3 R327-G301 study.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has presented new phase I clinical data for its cancer therapy candidate HMBD-002 at the American Association for Cancer Research Annual Meeting in San Diego, marking an important step forward for the company’s oncology program, which is “very well positioned” to progress, with $2.2 million in a recent raise expected to drive development work ahead of a targeted phase II study in calendar 2026.
The poster presentation outlined results from a completed phase I study of HMBD-002 in 48 patients with a range of advanced cancers across six US centres, providing the company with early clinical validation as it works towards the next stage of development.
Solis Minerals Ltd (TSX-V:SLMN, ASX:SLM, OTCQB:SLMFF, FRA:08WA) is expanding beyond Peru and into Brazil’s fast-emerging lithium sector through the acquisition of a large-scale exploration package in Minas Gerais, a move that broadens its exposure across battery metals and adds a second growth front alongside its copper portfolio.
The company has struck a deal to acquire 100% of the Brazil Lithium Project from a Rio Tinto subsidiary, securing a 93,000-hectare landholding in the Araçuaí-Salinas Lithium Valley, one of the world’s most active hard-rock lithium districts.